RoslinCT announces the establishment of a Cell and Gene Training Academy
RoslinCT – a cell and gene therapy/ATMP Contract Development and Manufacturing Organization (CDMO) – announces the establishment of the RoslinCT Training Academy. The Academy which comes as part of our expansion will allow us to develop a skilled team and to support our company growth and expansion plans.
The fitting out of the Academy, which is located within our new state of the art facility, is progressing well and will focus on upskilling the existing staff as well as providing external training as part of the Advanced Therapies Skills Training Network (ATSTN). Key to our success is our people and as we move through this phase of growth, we are developing a team and infrastructure to create high-value and develop potentially lifesaving treatments.
We are also proud that RoslinCT with our Training Academy has been selected to be leading the Scottish Group as one of three preferred bidders for National Training Centres, to deliver ATMP and Vaccine-specific on-site training courses, as part of the ATSTN.
Janet Downie, CEO of RoslinCT said: “With ATMP Manufacturing being at the cutting edge we have taken the strategy to provide the training internally and develop a highly-skilled RoslinCT team. We are delighted to be part of the ATSTN network and be able to share our knowledge more widely. With the tremendous growth in ATMP and Vaccine Manufacturing, we are proud to support a pipeline of talent to support the industry for Scotland and the UK.”
The new Training Academy is supported by Scottish Enterprise, with £100,000 in grant funding provided as a contribution towards fully equipping the new facility. David Leven, Head of High Value Manufacturing at Scottish Enterprise, said: “Despite the Covid-19 pandemic, the cell and gene therapy sector has continued to grow and prosper, with demand for manufacturing capacity continuing to increase.
It’s fantastic to see RoslinCT expand its manufacturing facilities and create this new training academy, which will benefit all of Scotland’s cell and gene therapy companies and enhance our global reputation for life sciences excellence.”
For more information, please contact:
Katerina Tsita
Marketing Executive
Tel: +44 (0)131 658 5189
Email: Katerina.Tsita@roslinct.com
Web: www.roslinct.com
About RoslinCT
RoslinCT is a leading Contract Development and Manufacturing Organisation (CDMO), offering a range of integrated services from technology transfer, process and assay development through to GMP manufacturing, storage, QP certification and batch release of cell-based therapies for clinical trials.
RoslinCT has the vision to lead the field in cell and gene therapy manufacturing and be the global partner of choice, building success on expert knowledge, progressive partnerships and with the drive to deliver life-changing cell-based products to patients in need. This together with a passion for innovation and a flexible and personalised approach enables RoslinCT to engage with leading cell and gene therapy developers and to provide support at every step of the cell therapy development journey.
